Addressing the High Cost of Patient Recruitment in Clinical Trials

As the industry seeks to reign in the high cost of drug development, one area with significant potential for cost savings is patient recruitment, typically responsible for about one-third of clinical trial costs.

Clinical study protocols are increasingly complex, and as a result, it now takes between 12 and 15 years for an investigational drug to go from lab to patient.³ Unfortunately, traditional recruitment methods—which rely primarily on direct-to-patient (DTP) marketing—are not keeping pace with demand, and researchers are unable to secure an adequate number of qualified participants on a timely basis. When recruitment goals are not met, trial delays ensue and costs increase.

Download Attachment